We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Axogen Inc | NASDAQ:AXGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.09 | -1.53% | 5.79 | 5.71 | 5.84 | 6.18 | 5.71 | 5.89 | 307,051 | 01:00:00 |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
Common Stock, $0.01 par value | AXGN | The Nasdaq Stock Market |
Item 5.07.
|
Submission of Matters to a Vote of Security Holders |
Name | For | Withheld | Broker Non-Votes | |||||||||||||||||
Karen Zaderej | 29,091,370 | 445,969 | 4,129,371 | |||||||||||||||||
Quentin Blackford | 27,266,688 | 2,270,651 | 4,129,371 | |||||||||||||||||
Gregory Freitag | 29,437,283 | 100,056 | 4,129,371 | |||||||||||||||||
Dr. Mark Gold | 29,453,251 | 84,088 | 4,129,371 | |||||||||||||||||
Alan Levine | 29,354,718 | 182,621 | 4,129,371 | |||||||||||||||||
Guido Neels | 28,733,848 | 803,491 | 4,129,371 | |||||||||||||||||
Paul Thomas | 29,303,029 | 234,310 | 4,129,371 | |||||||||||||||||
Amy Wendell | 29,098,765 | 438,574 | 4,129,371 |
For | Against | Abstentions | Broker Non-Votes | |||||||||||||||||
33,587,946
|
12,637 | 66,127 | — |
For | Against | Abstentions | Broker Non-Votes | |||||||||||||||||
28,572,945
|
857,699 | 106,695 | 4,129,371 |
For | Against | Abstentions | Broker Non-Votes | |||||||||||||||||
20,054,655
|
9,401,069 | 81,615 | 4,129,371 |
(d) Exhibits.
Exhibit No.
|
Description of Exhibit | |||||||
10.1 |
Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 31, 2021).
|
|||||||
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
AXOGEN, INC. | ||||||||
Date: May 10, 2021 | By: | /s/ Brad Ottinger | ||||||
Brad Ottinger | ||||||||
General Counsel and Chief Compliance Officer |
1 Year Axogen Chart |
1 Month Axogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions